Guanine-rich sequences of nucleic acids, including DNA and RNA, are known to fold into non-canonical structures named G-quadruplexes (G4s). Such arrangements of these macromolecular polymers are mainly located in telomeres and in promoter regions of oncogenes and, for this reason, they represent a potential target for compounds with therapeutic applications. In fact, the ligand-mediated stabilization of G4s inhibits telomerase and the activity of transcriptional machinery and counteracts cancer cell immortalization. Flavonoids, along with other classes of small molecules, have been previously tested for their ability to stabilize G4s, but the mechanism of their interaction has not been fully elucidated. In the current work, we report a multi-technique investigation on the binding of tosylated isoflavones obtained by the B-ring modification of compounds from Maclura pomifera to a telomeric DNA sequence. Our study demonstrates that such derivatization leads to compounds showing lower binding affinity but with an increased selectivity toward G4 with respect to double-stranded DNA. The binding mode to the macromolecular target G4 was studied by combining results from electrospray mass spectrometry binding studies, nuclear magnetic resonance experiments and computational simulations. Overall, our findings show that tosylation influences the selectivity toward the macromolecular target by affecting the interaction mode with the nucleic acid.
Cancer represents a leading cause of mortality globally, with its complex biological nature posing significant challenges for treatment. Central to cancer progression are molecular pathways that govern cellular function, among which protein phosphatase 2A (PP2A) plays a vital role. As a serine/threonine phosphatase, PP2A maintains cellular homeostasis by dephosphorylating a broad range of protein substrates and has emerged as a key tumor suppressor. However, PP2A activity can be physiologically inhibited by endogenous regulators such as the SE Translocation (SET) protein. Overexpression of SET has been associated with the loss of PP2A function, promoting hallmark features of cancer. Interestingly, targeting the PP2A/SET interaction has shown therapeutic potential. Indeed, inhibiting SET to reactivate PP2A may restore cellular regulation, induce apoptosis in tumor cells, and attenuate cancer progression. Research efforts have explored compounds such as the endogenous D-erythro-C18-ceramide and the drug fingolimod (FTY720), both known for their ability to reactivate PP2A. In this work, PP2A/SET complex models were generated through a computational approach and, using molecular docking, the interaction of potential SET inhibitors from a library of 26 alkoxy phenyl 1-propan-one derivatives (APPDs) was characterized. Additionally, absorption, distribution, metabolism, and excretion (ADME) predictions were performed to assess pharmacokinetic properties and therapeutic potential. Eventually, the predicted binding affinities were then correlated with biological data to assess the reliability of the models. These findings provide valuable insights into molecule–receptor interactions and lay the groundwork for developing inhibitors with encouraging therapeutic implications.
Oxidative stress and inflammation are key players in central nervous system (CNS) diseases and in neurodegeneration. In this field, the search for novel targets and therapeutic tools is wide open. In this study, the identification of potential inhibitors of phosphodiesterase 9 (PDE9), a target of growing interest in CNS diseases, was done by using a rational virtual screening approach that employed ligand‐ and structure‐based methodologies. Furthermore, a novel method to evaluate PDE9A activity based on high‐performance liquid chromatography (HPLC) was developed to address the need for a time‐ and cost‐effective assay to evaluate inhibitors. One of the candidates identified by virtual screening demonstrated potent enzymatic inhibition, and subsequent in vitro tests proved its significant PDE9A‐dependent anti‐neuroinflammatory effects as it acted on pro‐inflammatory mediators such as COX‐2, IL‐1β, TNFα, and IL‐6. The results of this multidisciplinary study underscore the potential of developing PDE9A inhibitors to modulate cyclic guanosine monophosphate (cGMP) signaling pathways implicated in neuroinflammation and also potentially in synaptic plasticity and cognitive functions, paving the way for novel PDE9A‐targeting inhibitors addressing neurodegenerative diseases.